Skip to navigation | Skip to main content | Skip to footer
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Professor Robert Hawkins (MA MB BS PhD FRCP) - personal details

Contact details

Professor Robert Hawkins

Role: Cancer Research UK Professor of Medical Oncology

Tel: +44 (0)161 446 3208


Cancer Research UK Manchester Institute
Faculty of Medical & Human Sciences
University of Manchester
c/o Paterson Institute for Cancer Research
Christie Hospital NHS Trust
Wilmslow Road
M20 4BX



Memberships of Committees and Professional Bodies

American Society for Gene Therapy (ASGT)
International Society for Biological Therapy of Cancer (ISBTC)
British Association for Cancer Research (BACR)
American Society for Clinical Oncology (ASCO)
European Society for Gene and Cell Therapy (ESGCT)
European Society for Medical Oncology (ESMO)


  •   MB, BS(London), MA, PhD, FRCP


Robert Hawkins is Cancer Research UK Professor and Director of Medical Oncology at the University of Manchester and Christie Hospital. His research interests are in gene and immunotherapy. In addition to clinical training at the Royal Marsden Hospital and Addenbrookes Hospital in Cambridge he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Medical Oncology at Addenbrooke’s Hospital in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, Professor Hawkins focuses on treating renal cancer and cancer of the oesophagus/stomach. He heads a clinical research group undertaking trials in these cancers and also a range of early phase clinical trials of biological agents including vaccines, antibodies and cellular therapy. He has major grants from Cancer Research UK, the Kay Kendall Leukaemia Fund and the European Union (he is Co-ordinator of the ATTACK project and coordinator of the ATTRACT integrated training network) and has published widely in scientific and clinical journals and is an inventor/co-inventor on several antibody related patents.

Professor Hawkins leads the development of a Cellular Therapeutics Unit based at the University of Manchester Incubator Building. This is a GMP unit that will provide cells for clinical trials.